Drugs like Ozempic already have a big impact on how much patients eat - and now they may be changing the way they shop and ...

- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...

Nature Institute to host Dungeons & Dragons class for grades 6-9 in Godfrey ...

The Lycée Michelet, a large school complex with 2,300 students, banned mobile phones in its hallways in April 2025. School ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

Emir Sanusi II expresses joy in learning, highlighting his pursuit of a law degree as a lifelong ambition and the importance ...

The surprising truth about corporate investment in housing.

Whistling Woods International will conduct entrance exams from January 28 to 31 for its July 2026 academic cycle for ...

Based on his performance in critical metrics, this wide receiver prospect has the best odds of success in the 2026 draft ...

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

MUM-of-one Jules Brown had tried everything to lose weight but in the end, it was one ‘miracle’ supplement that changed ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.